Therapies Archives - Oncology Central Oncology Central

A team of researchers from @SussexUni has identified novel biomarkers within the blood and suggest that their findings could pave the way for a blood test to diagnose #glioblastoma. https://t.co/gADywiw9Zp

View all

Jobs

Connecting talent with opportunity. View our featured jobs

View all

Combination therapy shows promise for drug-resistant acute lymphoblastic leukemia in mice

PARP inhibitors: study uncovers novel mechanism of action

REARRANGE trial shows benefits of flexible dosing pattern to treat refractory metastatic colorectal cancer

Could the common cold virus treat bladder cancer?

E.coli programmed to colonize tumors in mice and deliver immunotherapy

ASCO 2019: what should you look out for?

Novel drug could be world’s first treatment for a pediatric brain cancer

Tumor clonality and resistance mechanisms in EGFR mutation-positive NSCLC: implications for therapeutic sequencing

Addressing unmet needs in pancreatic cancer with Pascal Hammel

Treatment options for triple-negative breast cancer with Ahmad Awada

ESMO Breast Cancer 2019: should HER2-positive breast cancer treatment de-escalation be personalized?

ESMO Breast Cancer 2019: good outcomes in young women with aggressive breast cancer

Pembrolizumab for small-cell lung cancer: an interview with Hyun Cheol Chung

Hematological malignancy stem cell transplants: improving matches to reduce mortality

AACR19: umbralisib trial results give support for use as a marginal zone lymphoma drug

AACR19: HER2 targeted CAR-T cell therapy shows promise in advanced sarcomas patients

AACR19: mesothelin targeted CAR-T cell therapy – a possible treatment for solid tumors

Defining aggressive or early progressing non-oncogene-addicted non-small-cell lung cancer: a separate disease entity?

Pembrolizumab could effectively treat recurrent glioblastoma, study suggests

Palbociclib halts tumor growth in early breast cancer patients

Dual-action virus targets both cancer cells and associated fibroblasts

Promising Phase I trial for anti-HER2 antibody

NCRI 2018: Prostate cancer patients may prioritize the avoidance of side-effects over survival probability

What are the top 5 breast cancer advancements of 2018?

Login

Therapies

Must read